| INTRODUCTION
Chronic hepatitis B infection is a complex disease affecting approximately 257 million people worldwide. 1 The natural history of infection evolves through multiple phases, currently defined by clinical parameters including the patient's hepatitis B e antigen (HBeAg) status, the presence of hepatic inflammation (ALT, alanine aminotransferase levels), as well as HBV DNA levels. [2] [3] [4] Therapeutic strategies focus on achieving sustained virological control. Most patients are treated with nucleos(t)ide analogues and although these are potent antiviral agents, therapy is usually long term.
Hepatitis B e antigen seroconversion, defined by the loss of HBeAg, and the appearance of anti-HBe antibodies, is usually associated with suppression of HBV DNA to <2000 IU/mL, and reduction in risk of progression to advanced liver disease or hepatocellular carcinoma. [5] [6] [7] HBeAg seroconversion is also considered a necessary precursor to HBsAg loss, 8, 9 and has been recognised as a treatment end-point by international guidelines. 4, 10, 11 Despite this, little is known about the molecular events that precede HBeAg seroconversion, and it is not possible to accurately predict which patients are likely to achieve this outcome whilst on nucleos(t)ide analogue therapy. This is important, as patients who do not serologically respond are likely to require lifelong treatment to maintain viral suppression. Fried et al published a detailed analysis of on-treatment quantitative HBeAg levels in the setting of 48 weeks of pegylated interferon therapy, and showed that the magnitude of HBeAg decline could predict for HBeAg seroconversion (and non-response). 6 Whether HBeAg levels predict for HBeAg seroconversion during nucleos(t)ide analogue therapy is unknown.
Study GS-US-174-0103 (NCT00116805) was a randomised, double-blind, phase 3 study of 266 HBeAg-positive chronic hepatitis B patients with immune clearance disease that compared the antiviral efficacy of tenofovir disoproxil fumarate (TDF) vs adefovir dipivoxil (ADV) monotherapy for an initial 48 weeks, followed by open label TDF for a further 336 weeks. 12, 13 Primary clinical trial endpoints included plasma HBV DNA <400 copies/mL and histological improvement. HBeAg and/or HBsAg loss and seroconversion were secondary endpoints. The clinical outcomes at weeks 48 through 384 have been previously published. [12] [13] [14] [15] [16] The aim of this analysis was to evaluate the association between on-treatment quantitative HBeAg levels and serological outcomes among subjects enrolled in study GS-US-174-0103.
2 | ME TH ODS
| Patients
A total of 266 HBeAg-positive patients with chronic HBV infection were enrolled into GS-US-174-0103. 12 The current analysis included only those patients infected with the four major HBV genotypes A to D (n = 249); patients infected with other genotypes were excluded from the analysis due to small subject numbers, which would have confounded the analysis (n = 17). Of these, 235 had serum available at week 0, and 214 had serum available at week 24. 
| Viral load and serological characterisation
HBeAg levels were measured using the Roche Elecsys HBeAg assay (Roche Diagnostics, Mannheim, Germany). The upper limit of quantification was 6000 PEIU/mL and the lower limit was 0.3 PEIU/mL.
Serial dilution of serum was performed to obtain an exact level if the dynamic range of the test was exceeded. HBV viral load and HBsAg quantification were determined previously using the Roche COBAS TaqMan (Roche Diagnostics) and Abbott Architect (Abbott Laboratories, Chicago, IL, USA) platforms respectively. 12 The lower limit of detection for HBV DNA was 29 IU/mL, and for HBsAg was 0.05 IU/mL.
| PCR amplification and direct sequencing
To interrogate the association between presence of BCP (A1762T/ G1764A) and/or PC (G1896A) mutations, and HBeAg levels and treatment response, the PC/core region was amplified from baseline, and on-treatment samples to week 48, by PCR. Oligonucleotides were synthesised by Geneworks, Adelaide, Australia and first round primers were PC5 (5 0 -TCG CAT GGA GAC CAC CGT GA-3 0 ) and 1437 (5 0 -CAT GCT GTA GCT CTT GTT CC-3 0 ), second round primers were PC5 and 1094 (5 0 -CGA AAT AAG AAG ATG ACA TGG-3 0 ).
Samples were amplified in a 50 ll reaction containing 4 lL extracted DNA template, 1X Qiagen amplification buffer containing 
| Statistical analysis
Statistical analyses were performed using STATA 14.2 (StataCorp, College Station, TX, USA). Parametric data is reported as mean AE SD.
Non-parametric data is reported as median (interquartile range; IQR).
Categorical data is reported as number (%). Exploratory, bivariate analyses of outcome variables were conducted using parametric or nonparametric tests as appropriate for continuous data, and chi-square or
Fisher's exact test for categorical data. Where multivariate regression was used, all baseline variables were included in the model, with stepwise elimination of non-significant factors to create the final model.
Cox proportional hazards modelling was used to determine independent factors associated with on-treatment response. Bonferroni corrections for repeated measures testing were applied. A two-tailed P-value of .05 was considered statistically significant.
| RESULTS

| Cohort characteristics
The characteristics of the overall cohort have been described in detail previously. 12 Baseline and on-treatment samples from 200 patients were evaluated in this analysis; characteristics of those included did not differ significantly from those excluded (Table S1 ). Of these, 104
(52%) patients achieved HBeAg seroconversion by week 384 (Fig- ures S1 and S2). A total of 178 (89%) had at least 2 years of follow up, with 147 (74%) subjects completing the study (Table S2 ). The median time to HBeAg seroconversion was 80 weeks (IQR: 36-162).
Baseline predictors of HBeAg seroconversion were older age, HBV genotype A, and higher grade necro-inflammatory activity on liver histology (Table 1) . There was no association with other baseline variables including ALT, HBV DNA level or HBsAg level.
| Baseline HBeAg levels varied by genotype
Median HBeAg level was 1369 PEIU/mL (IQR: 300-3340) (3.14 log 10 PEIU/mL [IQR: 2.48-3.52]) across the cohort ( Figure 1A ). Only one sample required dilution to fall within the dynamic range of the HBeAg assay. The remainder returned results within range as tested on undiluted serum. There were no statistically significant differences in baseline virologic parameters between those who achieved HBeAg seroconversion vs not (Table 1) . Specifically, median HBeAg levels in those achieving seroconversion were 1690 PEIU/mL (IQR 187-3441) vs 1175 PEIU/mL (IQR 547-3001) in non-seroconversion participants (P = .95).
HBeAg levels at baseline varied by HBV genotype ( by population sequencing is presented in Table 1 .
The presence of BCP variants at baseline was associated with lower baseline HBeAg level, except for genotype B infection, although there were only four subjects in this group (Table 2 (Figure 2A ). There was no significant difference in the magnitude of HBV DNA decline by week 24 between the two groups.
To ascertain the optimal cut-off for HBeAg decline by week 24, the Youden index was calculated for all degrees of HBeAg decline at week 24 of treatment, showing that the association was strongest when HBeAg decline was ≥2.2 log 10 HBeAg PEIU/mL (Table 3 , Figure 3A ).
T The association between a decline in HBeAg to an absolute level of ≤10 PEIU/mL at week 24 and HBeAg seroconversion was also investigated. This cut-off was chosen as it intersected the lower tertiles of HBeAg values at week 24, and also coincided with previously published data. 6 Subjects achieving this HBeAg level had a significantly higher likelihood of seroconversion (Table 3 , Figure 3B ). Detailed information on the rates of HBeAg seroconversion according to both thresholds is presented in Table S3 . In addition, amongst HBeAg seroconverters, those achieving the ≥2.2 log 10 HBeAg PEIU/mL threshold did so after a median of 36 weeks (IQR: 24-80), whereas those who did not meet the threshold did so after a median of 108 weeks (IQR: 48-204), P = .0001.
| Multivariate modelling identified several factors independently associated with on-treatment HBeAg seroconversion
Using Cox proportional hazards modelling, increased likelihood of HBeAg seroconversion was independently associated with age (HR HBsAg loss. 18 The additional predictive value of on-treatment benefits. 4, 10, 11, 20 Whilst the 2.2 log 10 PEIU/mL decline threshold identified in this study has strong statistical significance, it will require prospective validation in future study cohorts.
Using population-based Sanger sequencing, we showed that BCP variants were common, being detected in 41% of the study cohort.
As previously observed, the detection of BCP variants was associated with lower HBeAg levels. 18 Conversely, the PC variant was The association between HBeAg kinetics and serological end-points is potentially relevant to clinical trial design for novel candidates aiming for HBV cure. 21 Assays to quantify HBeAg longitudinally should be included in biomarker discovery panels for clinical development studies, as identifying patients that are unlikely to respond serologically on nucleos(t)ide analogue therapy may enable early intervention with alternative treatments to promote seroconversion. Finally, HBeAg status has been associated with HCC risk. 22 The association between HBeAg decline and treatment response suggests a plausible role for HBeAg level as a marker for natural history-HBeAg levels may refine existing risk models. It will be important for future studies to evaluate the association between HBeAg level and HCC risk in the setting of nucleos(t)ide analogue therapy.
As the global HBV cure effort moves forward, biomarkers that identify subsets of patients who may more rapidly benefit from novel therapeutic interventions will be helpful. Measuring HBeAg levels at baseline and on treatment is a simple assay that may guide such interventions. As data characterising the anti-HBV immune response
were not available for the current study, we also suggest that future studies should investigate the correlation between HBeAg level, anti-HBV immunity and clinical outcomes.
The observations made are subject to several limitations. The first is that off-treatment samples from the parent study were not available to determine durability of serologic response. Second is the 
